Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced on October 20, 2025 that it has entered into a joint‑venture agreement with RedHill Biopharma Ltd. (NASDAQ: RDHL) to jointly commercialize Talicia®, an FDA‑approved oral capsule for the treatment of Helicobacter pylori infection in adults. Under the terms of the agreement, RedHill will contribute all of its Talicia assets, including the product’s growing international licenses and associated revenues, to the new jointly owned company. In return, Cumberland will provide $4 million in investment capital and assume responsibility for the product’s distribution and sales, recording all future product sales revenue.
Talicia is a fixed‑dose, all‑in‑one capsule that combines omeprazole, amoxicillin and rifabutin. The drug achieved FDA approval in November 2019 and has demonstrated eradication rates of over 90 % in two large Phase 3 studies. It enjoys eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is protected by patents extending through 2042. In 2024, Talicia generated $8 million in net revenue, and it is covered by 70 % of commercial plans and 60 % of government plans. The product is stocked in 1,700 CVS pharmacies nationwide, providing a ready distribution network.
The joint venture gives CPIX an immediate, high‑margin revenue stream and expands its gastroenterology portfolio into a market with strong growth potential. By leveraging its established national sales force, Cumberland can accelerate U.S. penetration of Talicia, while the $4 million capital infusion supports the joint company’s launch and marketing efforts. The partnership also diversifies CPIX’s product mix beyond its current specialty acute‑care and oncology focus, positioning the company for broader market reach and potential cross‑selling opportunities with its existing product lines.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.